AMT-101   Click here for help

GtoPdb Ligand ID: 11645

Immunopharmacology Ligand
Comment: AMT-101 is an orally deliverable IL-10-cholix fusion protein [1]. It combines the anti-inflammatory IL-10 with a nontoxic fragment of the cholix exotoxin from Vibrio cholerae. The exotoxin fragment facilitates delivery of the fusion protein selectively to the intestinal epithelium via transcytosis through intestinal enterocytes into the lamina propria, where it is intended to treat intestinal inflammatory diseases. IL-10 treatment is associated with dose limiting systemic toxicities including anemia and thrombocytopenia. AMT-101 was designed to overcome this limitation by restricting its IL-10 activity to within the GI tract.
No information available.
Summary of Clinical Use Click here for help
AMT-101 has progressed to clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04224857 SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101 Phase 1 Interventional Applied Molecular Transport
NCT04583358 Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) Phase 2 Interventional Applied Molecular Transport
NCT04741087 Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis Phase 2 Interventional Applied Molecular Transport